AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01171573 — intervention group
Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Venepuncture - Taking blood
Study NCT02497755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App for smartphone
Description: A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
Study NCT02497755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Study NCT03052673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
Study NCT03052673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
Study NCT00514917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
Study NCT00514917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 22.5 mg injection subcutaneously every 12 weeks up to 18 months.
Study NCT00514917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: 22.5 mg injection subcutaneously every 12 weeks up to 18 months.
Study NCT00514917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg tablet orally once daily for first 4 weeks of treatment.
Study NCT00514917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg tablet orally once daily for first 4 weeks of treatment.
Study NCT03556176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
Study NCT00749632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: high dose oxybutynin administered daily
Study NCT03045146 — intervention group
Intervention type: OTHER
Intervention: Multimodal brain imaging
Description: Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
Study NCT04350515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyberball: Other Exclusion
Description: A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.
Study NCT04350515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyberball: Player Exclusion
Description: A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.
Study NCT04350515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Emotion Regulation Task
Description: In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.
Study NCT04350515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Word Recognition Task
Description: In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task.
Study NCT02037945 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET Scan
Study NCT02426606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Various lentil varieties (varying in slow digested starch content)
Description: Randomized, cross-over block design.~Comparison of glycemic and insulinemic responses following meals composed of:~* white rice or white rice combined with 1 of 3 different lentil varieties or~* white potato or white potato combined with 1 of 3 different lentil varieties~Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.~Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit).
Study NCT02158533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study NCT02158533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study NCT02158533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study NCT04680923 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPPLAI
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
Study NCT04680923 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.
Study NCT04680923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
Study NCT03999970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sand fly bite
Description: Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
Study NCT03244098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Description: TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
Study NCT03243903 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QS-M insulin-free injector
Description: Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
Study NCT03243903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional insulin pen
Description: Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
Study NCT03852225 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-arrest echocardiography
Description: Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
Study NCT03476850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
Study NCT03476850 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
Study NCT04282577 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: urinary nephrin and alpha one microglobulin
Description: urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
Study NCT03556176 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiet rest
Description: Quiet rest during 30 min
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study NCT00208468 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: European Hip
Description: A cementless femoral component for use in total hip replacement
Study NCT00208468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zweymüller
Description: A cementless femoral component for use in total hip replacement
Study NCT00208468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLS Spotorno
Description: A cementless femoral component for use in total hip replacement
Study NCT02386423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTIFFIC™ Brand Pressure Application System
Description: The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
Study NCT02842814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug free
Description: Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
Study NCT02842814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
Study NCT02842814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC+HCQ
Description: Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
Study NCT03157557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Description: Lifestyle treatment
Study NCT00814710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses
Study NCT00814710 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 3 doses
Study NCT00814710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Intramuscular injection, 3 doses
Study NCT00814710 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 3 doses
Study NCT00484354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: IV bicarbonate given with amount based on patient weight
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT03769103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Daily oral osimertinib
Study NCT03769103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Daily oral osimertinib
Study NCT03769103 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiotherapy
Description: 1-5 fractions of stereotactic radiotherapy
Study NCT00484354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV Normal saline with volume given determined by patient weight
Study NCT00484354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: IV bicarbonate, dosed by weight
Study NCT00484354 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, with volume given based on patient weight
Study NCT01363050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
Study NCT00938548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75 mg orally
Study NCT00938548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Complex (placebo)
Description: Vitamin Complex orally
Study NCT04554576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish
Description: The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)
Study NCT04554576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish
Description: The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)
Study NCT04554576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote feedback active group
Description: After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)
Study NCT04554576 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote feedback control group
Description: After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.
Study NCT02638246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered, Incentive-based intervention + Motivational Interviewing
Description: Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
Study NCT02638246 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet-delivered, non-contingent incentives + Motivational Interviewing
Study NCT00662155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: sedative-hypnotic
Study NCT00662155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebo
Study NCT01797523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
Study NCT01797523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablet by mouth once daily in a 28 day cycle.
Study NCT01797523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg by mouth once daily in a 28 day cycle.
Study NCT04285528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthetia Fentanyl and Propofol
Description: Patients were anesthetized using Fentanyl (2 mcg per kg) and Propofol (1-2 mg per kg). Proper classic laryngeal mask airway was inserted afterwards.
Study NCT04285528 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PFK
Description: A mixture of 5 mcg/ml of Fentanyl, 5 mg/ml of Propofol, and 5 mg/ml of Ketamine was used. Each patient received an initial dose of 0.5 mg/kg from the solution, then after waiting for 60 seconds, another 0.5 mg/kg were given. Maintenance was given as boluses of 0.2- 0.33 mg/kg every three to five minutes. No Laryngeal mask airway nor endotracheal tube were inserted, and the patients were breathing spontaneously through a simple face mask on a support of 3 L/min O2.
Study NCT03166800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinone
Description: This arm of the intervention the study subject will be administered 40mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
Study NCT00016302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: Given IV
Study NCT03166800 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoquinone
Description: This arm of the intervention the study subject will be administered 20mg of the study drug MitoQ orally in capsule form every morning for 12 weeks.
Study NCT03575585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counselor Training
Description: 2 hours of training on how to use the BEST patient feedback report
Study NCT03575585 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Counselor Training
Description: Standard training (2 hrs) plus 8 additional hours (4 modules) of motivation/skills training on a) talking about sex with patients, b) basics of using Motivational Interviewing techniques to review a feedback report, c) teaching patients problem solving skills, and d) teaching patients relationship communication skills.
Study NCT03257956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Group
Description: The RHEA device and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03257956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reference group
Description: The reference device Earlysense 2.0 system(vital sign monitoring system) and Philips Patient Monitor MX400 are used to monitor the heart rate (HR) and respiratory rate (RR) of participants.
Study NCT03166800 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This arm of the intervention the study subject will be administered placebo capsules to orally take every morning for 12 weeks.
Study NCT00520026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lithium
Study NCT00520026 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00907907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate Mofetil Tablet 500 mg
Study NCT00907907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CellCept® Tablets
Description: CellCept® Tablets, 500 mg
Study NCT01955200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: (ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
Study NCT01955200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: (ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
Study NCT01955200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: (ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
Study NCT01955200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: (ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
Study NCT00641134 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: A: Home-Based exercise after Cardiac Rehabilitation
Description: Home-Based exercise program,after CR, with reinforcement sessions
Study NCT01152827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10 mg daily po medication.~Treatments will be continued until any of the following events occur~* progression of disease~* the subject develops unacceptable toxicity~* consent to participate in the study is withdrawn
Study NCT02158741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Visits and Lifestyle Education Support
Study NCT02595944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection